Tinnitus Therapies from Neurodegenerative Research

Over 740 million people worldwide experience tinnitus, a persistent phantom ringing or buzzing in the ears. Neuroscientists now believe this condition is less about the ear and more about the brain. A 2026 review by J L Liu and Peng Liu consolidates evidence that the brain changes underlying tinnitus share striking similarities with the processes that drive neurodegenerative diseases like Alzheimer’s. This fundamental insight opens a direct path to potential new treatments by repurposing drugs already in development for those conditions.

Why Tinnitus Shares Biology with Neurodegeneration

The core argument from Liu and Liu’s work is that both tinnitus and neurodegeneration involve “maladaptive neuroplasticity.” This means the brain’s networks rewire themselves in harmful, self-perpetuating ways. For tinnitus, sound deprivation from hearing loss can trigger a cascade of events in the central auditory system and connected brain regions. These events include chronic, low-level neuroinflammation—an immune response in brain tissue—and excitotoxicity, where nerve cells are damaged or killed by excessive stimulation, often from the neurotransmitter glutamate. This pattern is a hallmark of neurodegenerative pathology.

Furthermore, this dysfunction disrupts normal communication between key brain areas. This disruption aligns with models like thalamocortical dysrhythmia, a theory linking abnormal brain rhythms to both chronic pain and tinnitus. The shared mechanisms suggest that therapeutic strategies successful in one domain might benefit the other.

Three Key Repurposing Strategies for Tinnitus

The review systematically examines several neurodegenerative disease strategies with direct relevance to tinnitus models.

Targeting Neuroinflammation

Inflammatory molecules in the brain can amplify neuronal hyperactivity and sustain the tinnitus signal. Drugs that inhibit specific inflammatory pathways—such as TNF-α inhibitors or modulators of the NLRP3 inflammasome—have shown promise in preclinical tinnitus studies. By reducing this “brain inflammation,” researchers aim to quiet the overactive neural circuits responsible for phantom sound perception.

Modulating Neurotrophic Factors

Neurotrophic factors, like brain-derived neurotrophic factor (BDNF), act as growth and maintenance chemicals for neurons. In some neurodegenerative contexts, BDNF levels are too low. In early-stage tinnitus, however, BDNF can be paradoxically elevated, potentially contributing to maladaptive rewiring. The goal is to restore balance, either by supplementing deficient factors or, in the case of tinnitus, potentially modulating excessive BDNF signaling to stabilize neural networks.

Mitigating Glutamate Excitotoxicity

Glutamate is the brain’s primary excitatory neurotransmitter. Excessive glutamate release leads to excitotoxicity, a well-documented neuron killer in stroke and Alzheimer’s disease. In tinnitus, hyperactivity in the auditory pathway involves excessive glutamatergic signaling. Drugs that block specific glutamate receptor subtypes (like NMDA or AMPA receptors) are under investigation. The challenge is to reduce the pathological “noise” in the system without impairing essential brain functions like learning and memory, a hurdle also faced in neurodegeneration research.

From Animal Models to Human Trials

The evidence supporting these links is strongest in animal studies. Research in rodents with noise-induced hearing loss and tinnitus has demonstrated that drugs influencing these pathways can reduce behavioral measures of tinnitus. Translating these findings to humans is the critical next step.

Some clinical studies have begun. For instance, memantine, an Alzheimer’s drug that modulates glutamate signaling, has been tested in tinnitus patients with mixed results, highlighting the need for better patient stratification. Other anti-inflammatory agents used for autoimmune conditions are being considered for clinical trials in tinnitus. The approach mirrors strategies in Coordinated Reset Therapy, which aims to desynchronize pathological brain networks—another concept borrowed from computational neurology and applied to both Parkinson’s and tinnitus.

Practical Implications for Future Treatment

This repurposing strategy offers a pragmatic advantage. Drugs developed for neurodegeneration have already passed significant safety testing, potentially accelerating their path to new tinnitus applications. It moves the field beyond generic sound masking or counseling toward mechanism-based pharmacology.

The review by Liu and Liu calls for more targeted clinical trials that select tinnitus patients based on biomarkers or specific clinical profiles, such as those with strong central nervous system components. This precision medicine approach could identify which patients are most likely to respond to an anti-inflammatory versus an anti-excitotoxicity drug.

Furthermore, this brain-centric view reinforces why non-pharmacological brain-modulation treatments can be effective. Techniques that promote neuroplasticity and regulation, such as those discussed in our article on Mindfulness, Yoga, and Hypnosis for Tinnitus Relief, may work in concert with biological interventions by helping to retrain the brain’s response to the tinnitus signal. The shared foundation with neurodegeneration also invites exploration of lifestyle factors; for example, research on Cellular Senescence and Cognitive Aging Disparities highlights how systemic inflammation accelerates brain aging, a process that could theoretically influence tinnitus severity.

A Cohesive Path Forward

The work of Liu and Liu provides a cohesive framework: tinnitus can be viewed, in part, as a localized neurodegenerative-like process within auditory and associated limbic networks. This reframing is not merely academic. It directly enables the strategic borrowing of therapeutic candidates from a rich and well-funded adjacent field of neurology.

The next five years will likely see an increase in clinical trials testing repurposed neurodegenerative drugs for tinnitus. Success will depend on rigorously linking a drug’s molecular mechanism to the specific neuroplastic dysfunction present in individual tinnitus patients, moving closer to a future where treatment is tailored to the underlying cause of the phantom sound.

Source: Liu JL, Liu P. (2026). Repurposing Neurodegenerative Disease Therapeutic Strategies for Tinnitus Intervention: Mechanisms and Prospects. Front. Aging Neurosci. DOI: 10.3389/fnagi.2026.1835649.